Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the ...

Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy ...

Bernstein was taking part in the annual Long Beach Polar Bear Splash in memory of his daughter, who died at 20 after a struggle with muscular dystrophy.

The InterContinental Buckhead Hotel was filled with a powerful sense of purpose on Saturday, March 14, 2026, as the Muscular ...

At this time every year, students in Shelter Island’s National Honor Society sell shamrocks to raise money for the Muscular Dystrophy Association (MDA). MDA provides health care and support services ...

Longboat Key firefighters “filled the boot” through a fundraising effort for the Muscular Dystrophy Association.

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel ...

Keros Therapeutics will use the Massachusetts General Hospital MyMatch program to design a clinical trial testing rinvatercept for ALS.

Capricor Therapeutics (CAPR) upgraded to Buy as FDA accepts HOPE-3 for Deramiocel in DMD cardiomyopathy; PDUFA Aug 22, 2026. Click here to read more.

Earlier this month, Dyne Therapeutics Inc. (NASDAQ:DYN) announced important updates for its DMD and DM1 programs.

Regenxbio's gene therapy shows promise for Duchenne muscular dystrophy, Eli Lilly invests $3 billion in China for diabetes treatment, and China approves a brain-computer interface device. CVS' Aetna ...

Solid Biosciences’ SGT-003 is the only late‑stage program to show early cardiac benefit across biomarkers and function, according to William Blair.